Quick Links
- General Laws Conversion Table (2023) [PDF]
- Florida Statutes Definitions Index (2023) [PDF]
- Table of Section Changes (2023) [PDF]
- Preface to the Florida Statutes (2023) [PDF]
- Table Tracing Session Laws to Florida Statutes (2023) [PDF]
- Index to Special and Local Laws (1971-2023) [PDF]
- Index to Special and Local Laws (1845-1970) [PDF]
- Statute Search Tips
2014 Florida Statutes
Refractory and intractable epilepsy treatment and research.
“(1) As used in this section, the term “cannabidiol” means an extract from the cannabis plant that has less than 0.8 percent tetrahydrocannabinol and the chemical signature 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol, or a derivative thereof, as determined by the International Union of Pure and Applied Chemistry.
“(2) For the 2014-2015 fiscal year, $1 million in nonrecurring general revenue is appropriated to the Department of Health for the James and Esther King Biomedical Research Program and shall be deposited into the Biomedical Research Trust Fund. These funds shall be reserved for research of cannabidiol and its effect on intractable childhood epilepsy.
“(3) Biomedical research funding for research of cannabidiol and its effect on intractable childhood epilepsy shall be awarded pursuant to s. 215.5602, Florida Statutes. An application for such funding may be submitted by any research university in the state that has obtained approval from the United States Food and Drug Administration for an exploratory investigational new drug study of cannabidiol and its effect on intractable childhood epilepsy. For purposes of this section, the Biomedical Research Advisory Council created under s. 215.5602, Florida Statutes, shall advise the State Surgeon General as to the direction and scope of research of cannabidiol and its effect on intractable childhood epilepsy and the award of research funding.”